ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation

This post is also available in: Español (Spanish)

laboratorio

Marta Barrachina, researcher at  Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), leads ADmit Therapeutics.

ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias, and  advance the development of more targeted treatments. To learn more about the initiative visit the website at: AlzDiscovery.org/accelerator.

ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), located in Barcelona, which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.

CEO & Co-founder Marta Barrachina believes that “this investment shows the potential of the technology that we are developing and recognises the involvement of our team.”

Genesis Biomed supports ADmit in the journey to bring to market a quick and early diagnostic test to detect Alzhemeir’s biomarkers in blood. The biomarkers are not related to β-amiloide or Tau proteines. Read more about ADmit in the company’s web.